# TTK Healthcare share price today (TTK Healthcare Ltd, NSE: TTKHLTCARE)

> TTK Healthcare share price today: ₹927.50 at the NSE close on 4 November 2026, down 19.6% in a year. TTK Healthcare (NSE: TTKHLTCARE) is worth ₹1,311 crore, trades at a P/E of 18.0 and has closed between ₹768.40 and ₹1,157.70 over the past 52 weeks. > TTK Healthcare Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 3% of past readings. TTKHLTCARE · Pharma - Others · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/ttk-healthcare-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹927.50 (−19.6% in a year)
- P/E: 18.0× (lower than 97% of the last 11 years)
- Revenue (Sep 2026): ₹233 Cr (+14.2% on a year ago)
- Profit (Sep 2026): ₹223 Cr (+1,015.0% on a year ago)
- Operating margin: 1.6% (−1.0 points on a year ago)
- ROCE: 8%, FY26
- ROIC: 8.2%, against a 12.0% cost of capital: −3.8 points

The main question: profits are rising, but only −14% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the TTK Healthcare share price today? TTK Healthcare Ltd's share price was ₹927.50 at the close on 4 November 2026. It has been rising for 10 weeks. That is 9.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹768 and ₹1,158, and at that close it sat 41% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running. Over the last 11 years the share price moved +2% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at TTK Healthcare this quarter? Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), highest quarterly profit in 16 quarters and number of shareholders up 49% in a year. 1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹233 crore, +14.2% on a year earlier. 2. Highest quarterly profit in 16 quarters Profit of ₹223 crore in the September 2026 quarter is the highest of the last 16 quarters. 3. Number of shareholders up 49% in a year 23,993 shareholders in the September 2026 quarter, against 16,134 a year earlier. ## What are TTK Healthcare's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), TTK Healthcare reported revenue of ₹233 crore, up 14.2% from ₹204 crore a year earlier, and a profit of ₹223 crore, up 1,015.0% from ₹20.0 crore. ### TTK Healthcare results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹233 crore | ₹204 crore | +14.2% |
| Profit | ₹223 crore | ₹20.0 crore | +1,015.0% |
| Earnings per share | ₹157.80 | ₹14.43 | +993.6% |
| Operating margin | 1.6% | 2.6% | −1.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the TTK Healthcare share price history? TTK Healthcare closed at ₹927.50 on 4 November 2026, down 19.6% from ₹1,153.30 a year earlier (7 November 2025) and up 33.4% over five years. Its highest weekly close since March 2016 was ₹1,739.80 on 13 September 2024. ### TTK Healthcare share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹905.70 | +2.4% |
| 1 month ago · 1 Oct 2026 | ₹1,014.35 | −8.6% |
| 6 months ago · 8 May 2026 | ₹926.85 | +0.1% |
| 1 year ago · 7 Nov 2025 | ₹1,153.30 | −19.6% |
| 3 years ago · 3 Nov 2023 | ₹1,258.05 | −26.3% |
| 5 years ago · 4 Nov 2021 | ₹695.35 | +33.4% |
| 10 years ago · 4 Nov 2016 | ₹959.10 | −3.3% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹905.00 | +2.5% |
| Highest weekly close since March 2016 · 13 Sep 2024 | ₹1,739.80 | −46.7% |
| Lowest weekly close since March 2016 · 27 Mar 2020 | ₹304.25 | +204.8% |
| 52-week high (weekly close) · 14 Aug 2026 | ₹1,157.70 | −19.9% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹768.40 | +20.7% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on TTK Healthcare? 4 Nov 2026: TTK Healthcare closed at ₹927.50, up 2.4% on the week and down 8.6% on the month. Results for July to September 2026: Revenue up 14.2% and profit up 1,015.0% on a year earlier. ### Earlier

- 17 Jul 2026: ex-date for a dividend of ₹10 a share. ## What dividend does TTK Healthcare pay? TTK Healthcare paid ₹10 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 1.08% at the ₹927.50 close on 4 November 2026. The last was a dividend of ₹10 a share, ex-date 17 July 2026. ### TTK Healthcare dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 17 Jul 2026 | ₹10 | Dividend |
| 18 Jul 2025 | ₹10 | Dividend |
| 16 Jul 2024 | ₹10 | Dividend |
| 18 Jul 2023 | ₹10 | Dividend |
| 26 Jul 2022 | ₹10 | Dividend |
| 12 Aug 2021 | ₹6 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. TTK Healthcare Ltd paid out 22% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## Which stock lists is TTK Healthcare on? TTK Healthcare is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 1310.3639677454987](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is TTK Healthcare profitable? TTK Healthcare Ltd earned ₹223 Cr of net profit in the Sep 2026 quarter, +1,015.0% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹66.0 Cr. Over 10 years profit has grown 11.1% a year on average. That is 95.7% of the quarter's revenue. The same quarter a year earlier earned ₹20.0 Cr. For the full year, FY26 profit was ₹66.0 Cr (−19.5% on the year before). Why profit moved: revenue changed +14.2% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +269.7% and revenue +11.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does TTK Healthcare make, and is it growing? TTK Healthcare Ltd reported ₹233 Cr of revenue in the Sep 2026 quarter, +14.2% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 5.1% a year on average. The last full year, FY26, came in at ₹857 Cr. The last four reported quarters add to ₹918 Cr. FY26 revenue was ₹857 Cr, +7.0% on the year before. Recent pace: the last four quarters grew +11.3% on average, against 5.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.3%, against +9.1% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +319.7%, against +86.1% a year (accelerating). ## How much of every ₹100 of sales does TTK Healthcare keep? TTK Healthcare Ltd's operating margin was 1.6% in the Sep 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 3.0% and 8.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −1.0 percentage points on the year while gross margin changed −0.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is TTK Healthcare's profit turning into cash? Over the last 3 years TTK Healthcare Ltd's operations used more cash than they brought in, so cash conversion was −14%, a gap worth watching. In FY26 its operations used ₹21.0 Cr of cash, against ₹66.0 Cr of profit. After ₹2.0 Cr of spending on assets, free cash was −₹23.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why −14% of profit came in as cash: the cash cycle got 65 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 65 days longer. The next section looks at where the cash is stuck. ## Where does TTK Healthcare's cash go? TTK Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 63 days in FY26, up from −2 days in FY21. It spent ₹30.0 Cr on assets over the last 3 years. Customers take 47 days to pay, and stock sits for 98 days on average. At FY26 sales of ₹857 Cr, each day of that cycle ties up about ₹2.3 Cr, so roughly ₹148 Cr is tied up in the business at any time. FY26: customers took 47 days to pay and stock sat for 98 days, about 3.2 months of sales sitting as stock, for a full cycle of 63 days, longer than FY21's −2. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 98 days. Customers pay about 47 days after that. Suppliers are paid at 83 days. Together that makes the 63-day cycle. Spending on assets: ₹30.0 Cr over the last 3 years, against ₹30.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹1.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is TTK Healthcare's P/E ratio, and how does it compare with its own history? TTK Healthcare Ltd's P/E is 18.0×, near the low end of its own history: it has been lower only 3% of the time. Its usual P/E (the middle reading) is 32.9×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −19.6% while the price moved −19.6%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +5.9% a year; about +24.4% a year came from earnings growth and about −18.5 percentage points from the multiple (the market paying less); over 10 years the price moved −0.3% a year; about +5.5% a year came from earnings growth and about −5.8 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the TTK Healthcare business getting better or worse? TTK Healthcare Ltd's business is giving mixed signals. Growth has been steadily positive, but ROCE at 8.9% is below the 15% level needed to call it steady growth. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. ## How much does TTK Healthcare earn on its capital? TTK Healthcare Ltd earned a ROCE of 8% in FY26. That is up from a low of 6% in FY21. Its return on capital used (ROIC) is 3.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 7.7% net margin and 0.64× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 7.7% net margin × 0.64× asset turnover × 1.19× leverage (assets divided by equity) ≈ 5.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 8.2% − 12.0% = −3.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 8.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 6.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does TTK Healthcare have too much debt? TTK Healthcare Ltd has total debt of ₹24.0 Cr against shareholder equity of ₹1,115 Cr as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.07 in FY22 to 0.02 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the TTK Healthcare shareholding pattern? Domestic institutions cut their stake in TTK Healthcare Ltd by 1.0 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 0.1% of the company. Foreign institutions moved +0.1 points over the same period, to 1.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −1.0 points over 8 quarters, to 0.1%; Foreign institutions: +0.1 points over 8 quarters, to 1.9%; Promoters: +0.0 points over 8 quarters, to 74.6%. Why the owners changed: domestic institutions drove it (−1.0 points). They reduced their stake. ## How far is TTK Healthcare from balance-sheet trouble? For TTK Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does TTK Healthcare rank in its industry? 50.7 out of 100, rank 5 of 10 in Pharma - Others, with 85% of the evidence available. TTK Healthcare Ltd scores 50.7 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 5. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 19.8 + 6.8 + 15.7 + 8.4 = 50.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is TTK Healthcare compared with? TTK Healthcare ranks 5 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 50.7 out of 100. 1. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) SYNCOMF · breaking out · Most evidence points up · 89% evidence 71.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 0.4% · Profit 48.3% · Operating margin change 7 points · 88% evidence Capital efficiency 17.8/25 · ROCE 24.7% · Operating margin 21% · 100% evidence Valuation 15.1/20 · P/E 21.2× · PEG 0.79 · 65% evidence Relative strength 17.8/20 · Lead over its industry -0.2% · Lead over NIFTY 500 32.3% · 1 year 16.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 17.8 + 15.1 + 17.8 = 71.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) SHUKRAPHAR · breaking out · Too little evidence to rank firmly · 56% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 100% · Profit 100% · Operating margin change 66 points · 83% evidence Capital efficiency 19.4/25 · ROCE 37% · Operating margin 90% · 76% evidence Valuation 9.3/20 · P/E 91.9× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 83.7% · 1 year 82.8% · 25% evidence · 6 of 6 weeks ahead Exact sum: 28.5 + 19.4 + 9.3 + 12.5 = 69.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) SPARC · quiet · Evidence leans up · 78% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 100% · Profit 100% · Operating margin change 455 points · 65% evidence Capital efficiency 16.3/25 · ROCE 164% · Operating margin -85% · 100% evidence Valuation 15.0/20 · P/E 3.6× · PEG n/a · 50% evidence Relative strength 4.3/20 · Lead over its industry -17.4% · Lead over NIFTY 500 9.3% · 1 year 30.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 25.8 + 16.3 + 15 + 4.3 = 61.4 · What this means: Earnings are strong; relative strength in its sector is -17.4% and the one-year return is 30.9%. 4. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) REMUS · breaking out · Too little evidence to rank firmly · 54% evidence 54.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 57.3% · Profit 80% · Operating margin change -4 points · 27% evidence Capital efficiency 13.3/25 · ROCE 11.5% · Operating margin 32% · 57% evidence Valuation 11.2/20 · P/E 41.2× · PEG n/a · 50% evidence Relative strength 12.8/20 · Lead over its industry -12.6% · Lead over NIFTY 500 16.6% · 1 year 17.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.5 + 13.3 + 11.2 + 12.8 = 54.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. TTK Healthcare Ltd this page TTKHLTCARE · quiet · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 11.3% · Profit 100% · Operating margin change -1 points · 100% evidence Capital efficiency 6.8/25 · ROCE 8% · Operating margin 1.6% · 100% evidence Valuation 15.7/20 · P/E 17.6× · PEG 1.38 · 100% evidence Relative strength 8.4/20 · Lead over its industry n/a · Lead over NIFTY 500 -3% · 1 year -23.1% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19.8 + 6.8 + 15.7 + 8.4 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) UNICHEMLAB · losing its lead · Evidence leans down · 64% evidence 38.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.4/35 · Revenue 7.2% · Profit 100% · Operating margin change 6.7 points · 62% evidence Capital efficiency 6.6/25 · ROCE 4.1% · Operating margin 11% · 76% evidence Valuation 10.0/20 · P/E 27.9× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -13.3% · Lead over NIFTY 500 15.4% · 1 year 2.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.4 + 6.6 + 10 + 8.3 = 38.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) PANACEABIO · basing · Most evidence points down · 76% evidence 20.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.2/35 · Revenue 10.3% · Profit -80% · Operating margin change 3.5 points · 88% evidence Capital efficiency 1.2/25 · ROCE -2.4% · Operating margin 2.8% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 1.0/20 · Lead over its industry -38.3% · Lead over NIFTY 500 -16.4% · 1 year -28.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 8.2 + 1.2 + 10 + 1 = 20.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) leader · Too little evidence to rank firmly · 48% evidence 59.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.1/43.75 · Revenue 100% · Profit 100% · Operating margin change 53.1 points · 62% evidence Capital efficiency 17.4/31.25 · ROCE 16.8% · Operating margin 44.7% · 95% evidence Valuation 11.1/25 · P/E 219× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.1 + 17.4 + 11.1 = 59.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) Too little evidence to rank firmly · 47% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/43.75 · Revenue 11.8% · Profit 6.1% · Operating margin change 6 points · 53% evidence Capital efficiency 21.5/31.25 · ROCE 27.2% · Operating margin 32% · 71% evidence Valuation 14.3/25 · P/E 13.2× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.6 + 21.5 + 14.3 = 56.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) MADHUVEER · Too little evidence to rank firmly · 33% evidence 42.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.5/43.75 · Revenue 68.7% · Profit 12.8% · Operating margin change 18.4 points · 45% evidence Capital efficiency 11.7/31.25 · ROCE -1.1% · Operating margin 69.7% · 57% evidence Valuation 10.6/25 · P/E 660× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.5 + 11.7 + 10.6 = 42.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Others](https://www.sectoralpha.in/sectors/pharma-others), all 10 compared on one page. ## Which companies are close to TTK Healthcare in size? TTK Healthcare is the 7th largest of 10 Pharma - Others companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Panacea Biotec, Syncom Formulations (India) and JOJO. Just below it: Remus Pharmaceuticals, Madhuveer Com 18 Network and Jenburkt Pharmaceuticals. ### Pharma - Others companies close in size

1. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) ₹1,919 crore
2. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) ₹1,809 crore
3. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) ₹1,539 crore
4. TTK Healthcare Ltd ₹1,279 crore
5. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) ₹994 crore
6. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) ₹581 crore
7. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) ₹498 crore

[All 10 Pharma - Others companies, largest first](https://www.sectoralpha.in/sectors/pharma-others#all-companies)

### Companies close in size in other industries

1. [Chamanlal Setia Exports Ltd](https://www.sectoralpha.in/stocks/chamanlal-setia-exports-ltd) ₹1,285 crore · FMCG - Rice
2. [Seshasayee Paper & Boards Ltd](https://www.sectoralpha.in/stocks/seshasayee-paper-boards-ltd) ₹1,279 crore · Paper
3. TTK Healthcare Ltd ₹1,279 crore
4. [Go Fashion (India) Ltd](https://www.sectoralpha.in/stocks/go-fashion-indialtd) ₹1,276 crore · Textiles - Readymade Apparel
5. [Avishkar Infra Realty Ltd](https://www.sectoralpha.in/stocks/avishkar-infra-realty-ltd) ₹1,271 crore · Construction - Factories/Offices/Commercial

## What else do people ask about TTK Healthcare? ### What is TTK Healthcare's share price today? TTK Healthcare Ltd's share price is ₹927.50, −19.6% over the past year. The whole company is worth ₹1,311 Cr on the market. In the last 52 weeks it traded between ₹768 to ₹1,158; today it is 41% of the way up from the low, 9.2% below its 200-day average (as of 4 November 2026). ### What were TTK Healthcare's latest quarterly results? TTK Healthcare Ltd reported revenue of ₹233 Cr and net profit of ₹223 Cr for the Sep 2026 quarter. Revenue rose 14.2% and profit rose 1,015.0% compared with a year earlier. Earnings per share were ₹157.80. The operating margin was 1.6%, 1.0 percentage points lower than a year earlier (as of 4 November 2026). ### What is TTK Healthcare's market cap? TTK Healthcare Ltd's market capitalisation is ₹1,311 Cr at a share price of ₹927.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is TTK Healthcare performing? TTK Healthcare Ltd's share price has been rising for 10 weeks. In its latest quarter, revenue rose 14.2% and profit rose 1,015.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 2 weeks running (as of 4 November 2026). ### Will TTK Healthcare's share price go up? This page does not forecast TTK Healthcare Ltd's share price. What it shows instead: the share price is ₹927.50, and it has been rising for 10 weeks. Its P/E of 18.0× is higher than 3% of its own last 11 years (as of 4 November 2026). ### Who owns TTK Healthcare? Promoters own 74.6% of TTK Healthcare Ltd, foreign institutions 1.9%, domestic institutions 0.1% and the public 23.4% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 1.0 percentage points over 8 quarters (as of 4 November 2026). ### Where is TTK Healthcare in its business cycle? TTK Healthcare Ltd's FY26 operating margin was 3.0%, against a 13-year range of 3.0% to 8.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 1.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the TTK Healthcare story? The main question: profits are rising, but only −14% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is TTK Healthcare a stock worth studying right now? What the numbers show: TTK Healthcare Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 3% of past readings. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.